Abstract
Aim: Greenlight photoselective vaporization of the prostate (PVP) is considered a safe alternative to transurethral resection of the prostate (TURP) in men with lower urinary tract symptoms (LUTS) and a prostate volume of 30-80 mL for the comparable short- and mid-term results. Long-term re-treatment rate is still being debated.
Highlights
Benign prostatic obstruction (BPO) causing lower urinary tract symptoms (LUTS) is present in up to 80% of men over the age of 80 and in up to 50% of men over the age of 50, resulting in significant economic burden and potentially negative impact on the quality of life[1]
We retrospectively reviewed all cases undergoing standard or anatomical greenlight laser photoselective vaporization of the prostate for lower urinary tract symptoms secondary to BPO, using the 180-W Xcelerated Performance System (XPS) GL system, in a multi-institutional, prospectively collected database performed in 20 Italian centers from September 2011 to December 2019, and collecting data on patients developing LUTS relapse requiring reintervention (TURP or greenlight PVP) with a follow-up period of at least 12 months
Patients with all the following data were considered in the statistical analysis: age, prostate volume evaluated with trans-rectal ultrasound (TRUS), use of antiplatelet and anticoagulant medications, LUTS therapy and history of catheterization or retention, PSA level, IPSS, maximum urinary flow (Qmax), operative time, lasing time, catheterization time, hospital stay, and complications
Summary
Benign prostatic obstruction (BPO) causing lower urinary tract symptoms (LUTS) is present in up to 80% of men over the age of 80 and in up to 50% of men over the age of 50, resulting in significant economic burden and potentially negative impact on the quality of life[1]. Despite the availability of several laser technologies (holmium, greenlight, diode, and thulium), monopolar or bipolar transurethral resection of the prostate (M- or B-TURP) is considered the first-line treatment for patients with moderate-to-severe LUTS and a prostate volume of 30-80 mL, due to the absence of long-term surgical randomized controlled trials on laser treatments[2]. According to the current literature, the major limitation of greenlight is the absence of long-term follow-up (≥ 36 months) data to evaluate the outcome, the rate of re-intervention, and patient satisfaction For these reasons, we decided to review and update our large multicenter cohort of patients who have undergone greenlight laser treatment in order to analyze the long-term re-treatment rate and risk factors for treatment failure
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
